Lisata Therapeutics to Advance AI-Discovered Opioid Use Disorder Therapeutic into Human Clinical Trials by Early 2026

Reuters

2025/06/17

Lisata <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to Advance AI-Discovered Opioid Use Disorder Therapeutic into Human Clinical Trials by Early 2026

Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company, has announced plans to advance a new therapeutic for opioid use disorder (OUD) into human clinical trials early in 2026. This initiative arises from a strategic alliance with GATC Health Corp., leveraging GATC's AI-powered Multiomics Advanced Technology® platform. The AI-discovered therapeutic, a non-opioid small molecule, has shown a significant reduction in fentanyl intake during preclinical studies in murine models. Lisata will lead the development efforts, contributing its expertise in drug development and regulatory processes. The upcoming Phase 1 human trials will aim to validate the therapeutic's efficacy and safety, marking a significant step in the collaboration's objective to accelerate and enhance the success rate of drug development. Results from these trials have not yet been presented and are anticipated following the commencement of the trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9469697-en) on June 17, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2544962815"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544962815\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544962815?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-17 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544962815","market":"fut","top_or_hot":-1,"title":"Lisata Therapeutics to Advance AI-Discovered Opioid Use Disorder Therapeutic into Human Clinical Trials by Early 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lisata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Advance AI-Discovered Opioid Use Disorder Therapeutic into Human Clinical Trials by Early 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company, has announced plans to advance a new therapeutic for opioid use disorder (OUD) into human clinical trials early in 2026. This initiative arises from a strategic alliance with GATC Health Corp., leveraging GATC's AI-powered Multiomics Advanced Technology® platform. The AI-discovered therapeutic, a non-opioid small molecule, has shown a significant reduction in fentanyl intake during preclinical studies in murine models. Lisata will lead the development efforts, contributing its expertise in drug development and regulatory processes. The upcoming Phase 1 human trials will aim to validate the therapeutic's efficacy and safety, marking a significant step in the collaboration's objective to accelerate and enhance the success rate of drug development. Results from these trials have not yet been presented and are anticipated following the commencement of the trials.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9469697-en) on June 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lisata Therapeutics to Advance AI-Discovered Opioid Use Disorder Therapeutic into Human Clinical Trials by Early 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLisata Therapeutics to Advance AI-Discovered Opioid Use Disorder Therapeutic into Human Clinical Trials by Early 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-17 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lisata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Advance AI-Discovered Opioid Use Disorder Therapeutic into Human Clinical Trials by Early 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company, has announced plans to advance a new therapeutic for opioid use disorder (OUD) into human clinical trials early in 2026. This initiative arises from a strategic alliance with GATC Health Corp., leveraging GATC's AI-powered Multiomics Advanced Technology® platform. The AI-discovered therapeutic, a non-opioid small molecule, has shown a significant reduction in fentanyl intake during preclinical studies in murine models. Lisata will lead the development efforts, contributing its expertise in drug development and regulatory processes. The upcoming Phase 1 human trials will aim to validate the therapeutic's efficacy and safety, marking a significant step in the collaboration's objective to accelerate and enhance the success rate of drug development. Results from these trials have not yet been presented and are anticipated following the commencement of the trials.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9469697-en) on June 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"纳斯达克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nNDL25vvBd:1","article_id":"2544962815","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544962815","pubTimestamp":1750161645,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lisata Therapeutics, Inc. , a clinical-stage pharmaceutical company, has announced plans to advance a new therapeutic for opioid use disorder  into human clinical trials early in 2026. This initiative arises from a strategic alliance with GATC Health Corp., leveraging GATC's AI-powered Multiomics Advanced Technology platform. The AI-discovered therapeutic, a non-opioid small molecule, has shown a significant reduction in fentanyl intake during preclinical studies in murine models. Lisata will lead the development efforts, contributing its expertise in drug development and regulatory processes. The upcoming Phase 1 human trials will aim to validate the therapeutic's efficacy and safety, marking a significant step in the collaboration's objective to accelerate and enhance the success rate of drug development. Results from these trials have not yet been presented and are anticipated following the commencement of the trials.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","BK4139":"生物科技","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LSTA":"LISATA THERAPEUTICS INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"Lisata Therapeutics将于2026年初将人工智能发现的阿片类药物使用障碍疗法推进人体临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LSTA":0.9,"NDAQ":0.9},"content_text":"Lisata Therapeutics to Advance AI-Discovered Opioid Use Disorder Therapeutic into Human Clinical Trials by Early 2026\n    \n\n        Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company, has announced plans to advance a new therapeutic for opioid use disorder (OUD) into human clinical trials early in 2026. This initiative arises from a strategic alliance with GATC Health Corp., leveraging GATC's AI-powered Multiomics Advanced Technology® platform. The AI-discovered therapeutic, a non-opioid small molecule, has shown a significant reduction in fentanyl intake during preclinical studies in murine models. Lisata will lead the development efforts, contributing its expertise in drug development and regulatory processes. The upcoming Phase 1 human trials will aim to validate the therapeutic's efficacy and safety, marking a significant step in the collaboration's objective to accelerate and enhance the success rate of drug development. Results from these trials have not yet been presented and are anticipated following the commencement of the trials.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9469697-en) on June 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}